Open AccessCFTR founder mutation causes protein trafficking defects in Chinese patients with cystic fibrosis
Author(s) -
Leung Gordon K. C.,
Ying Dingge,
Mak Christopher C. Y.,
Chen XinYing,
Xu Weiyi,
Yeung KitSan,
Wong WaiLap,
Chu Yoyo W. Y.,
Mok Gary T. K.,
Chau Christy S. K.,
McLuskey Jenna,
Ong Winnie P. T.,
Leong HueyYin,
Chan Kelvin Y. K.,
Yang Wanling,
Chen JengHaur,
Li Albert M.,
Sham Pak C.,
Lau YuLung,
Chung Brian H. Y.,
Lee SoLun
Publication year - 2017
Publication title -
molecular genetics and genomic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.765
H-Index - 29
ISSN - 2324-9269
DOI - 10.1002/mgg3.258
Subject(s) - missense mutation , mutation , cystic fibrosis , mutant , genetics , haplotype , mutant protein , biology , exome sequencing , microbiology and biotechnology , medicine , gene , allele
Background Cystic fibrosis ( CF ) is a rare condition in Asians. Since 1985, only about 30 Chinese patients have been reported with molecular confirmation. Method Using our in‐house next‐generation sequencing ( NGS ) pipeline for childhood bronchiectasis, we identified disease‐causing CFTR mutations in CF patients in Hong Kong. After identifying p.I1023R in multiple patients, haplotype analysis was performed with genome‐wide microarray to ascertain the likelihood of this being a founder mutation. We also assessed the processing and gating activity of the mutant protein by Western hybridization and patch‐clamp test. Results Molecular diagnoses were confirmed in four patients, three of whom shared a missense mutation: CFTR :c.3068T>G:p.I1023R. The results suggested that p.I1023R is a founder mutation in southern Han Chinese. In addition, the processing and gating activity of the mutant protein was assessed by gel electrophoresis and a patch‐clamp test. The mutant protein exhibited trafficking defects, suggesting that the dysfunction is caused by reduced cell surface expression of the fully glycosylated proteins. Conclusion Together with other previously reported mutations, the specific founder mutation presented herein suggests a unique CFTR mutation spectrum in the southern Chinese populations, and this finding has vital implications for improving molecular testing and mutation‐specific treatments for Chinese patients with CF .